Top Tweets for #panCAN
Nationwide Fully Decentralized Telemedicine Therapeutic Trial for Advanced Pancreatic Cancer: Implementation and First Enrollment.
Read the full article. https://t.co/9uohlWXXAH
#pancan
Heading to #PanCAN Summit in San Diego? We’re sharing research on using pan-cancer transcriptomics + AI/machine learning to advance personalized treatment response assessment in pancreatic cancer.
📅 Sept. 24 | 6:30–8:30 PM
📍 Bivouac Ballroom, US Grant Hotel
#PrecisionOncology #CancerResearch #OncologyCopilot
Daraxonrasib in Pancreatic Cancer: From Second-Line Breakthrough to First-Line Evidence.
Read the full article. https://t.co/gpZZzE1PGb
#pancan
Thrilled about this new drug approval for the #PanCan community. So many cancers are driven by RAS, so this may lead to advances in many areas.
The FDA 🇺🇸 approved daraxonrasib, a first-in-class RAS inhibitor, for adults with metastatic pancreatic adenocarcinoma who have received prior systemic therapy or cannot receive multiagent treatment. Taken daily, the drug targets RAS proteins that drive tumor growth.
✅️ The approval, issued ahead of schedule, provides a new treatment option for a cancer with limited therapies and poor outcomes. #PancreaticCancer
https://t.co/Iv2XGawyFI
@CathyEngMD
@BenWestphalen
@graokane
@NiuSanford
@AndresC27622123
@GillSharlene
@pashtoonkasi
@DrVilmaPBarcia
@Erman_Akkus
@GIMedOnc
@UOzkerim
@MarioBalsaMD
@p_ciracimd
@DraMartinezLago
@DaisukeKotani
@Aiims1742
@ARosen380
@realbowtiedoc
@KoheiShitara
@MarioBalsaMD
@realbowtiedoc
@p_ciracimd
@c_eng1
@sharlenegill
@alicat380
@erman_akkus__
@ninan1230
@shitarakohei
@jaketapper @BenSasse Amazing news! Lost my dad to metastatic pancreatic cancer in 2011. He was only given two treatment options. He died 9 mos. later. Have been waiting for the day when those impacted by this disease are given hope upon dx, not a death sentence. 🙌 #pancan
My dad was given a death sentence upon diagnosis of metastatic pancreatic cancer in 2010. This is amazing news and just the beginning! #pancreaticcancer #pancan
A RAS inhibitor called Rasonque™ (daraxonrasib) is approved for the treatment of adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy. This is now considered the new standard of care for patients with previously treated metastatic pancreatic cancer after clinical trial results in this population showed a doubling of survival compared to chemotherapy as well as improved quality of life for patients.
PanCAN Chief Scientific and Medical Officer @ABerkenblit, MD, MMSc shares, “The FDA approval of Rasonque™ is the most significant advancement we have ever seen in the fight against pancreatic cancer. This drug will transform how we treat pancreatic cancer – giving people the opportunity for more time with loved ones, the possibility of a better quality of life and renewed confidence that continued research will deliver even greater advances.”
We are here to help. 💜 Contact PanCAN Patient Services for one-to-one support and free information about the disease and treatment options.
Breaking News: The FDA approved a first-of-its-kind pill that could substantially extend the lives of patients with pancreatic cancer. https://t.co/IVgybALGXh
Top Advances of the Year commentary 💡 Authors from @UTMDAnderson critically review recent & emerging data that have helped to define the current state of neoadjuvant management in pancreatic cancer: https://t.co/5GWboyZiVR
@OncoAlert #pancan
With 2L #daraxonrasib under FDA review for mPDAC, the future is shifting towards earlier use and personalized combos (KRAS G12D, MTAP loss). Looking forward to seeing where the research takes us! #MedOnc #PanCan #GITwitter
AIM ImmunoTech Reports Positive Mid-Year Interim Clinical Progress from Phase 2 Study Evaluating Ampligen® (rintatolimod) in Combination with AstraZeneca’s Imfinzi® (durvalumab) for the Treatment of Pancreatic Cancer
https://t.co/bTIC8yKDnU
$AIM #PancreaticCancer #PanCan
$nwbo @alphavestcap
@andrewcaravello·Jan 23Show more#KRAS Stack and #KEYTRUDA Need Dendritic Cell Instruction in #PanCAN 📷 TLDR Dr. Elizabeth Jaffee’s title is a structural assertion, not a marketing one. The cancer🧬 The Cancer Vaccine Era Has Arrived: How Jaffee’s Map Converges with $NWBO #Murcidencel #DCVax, and Why$MRKQuoted_stock@d_stock07734·Jan 21$NWBO World-Leading Tumor Immunologists Nina Bhardwaj and Elizabeth Jaffee Appointed Associate Directors of the Cancer Research Institute Scientific Advisory Council https://t.co/bbyEtTeHqI Abstract 3102A: Analysis of spatial relationships between infiltrating immune cellsAndrew Caravello, DO@andrewcaravelloplease explain how this post describes an immune bypass in pancreatic cancer rather than a traditional immune stimulant. Use DCVax as the reference architecture and contrast it with GVAX. Write for a scientifically literate audience. Frame the conclusion in terms of systems engineering or control theory applied to immunology.@grok Views10:15 AM · Jan 23, 2026·195Grok📷@grok·Jan 23The thread highlights an immune bypass strategy in PDAC by addressing dendritic cell (DC) dysfunction in the suppressive tumor microenvironment (TME), where endogenous DCs often fail to mature properly or produce IL-12, leading to weak T-cell priming. DCVax serves as the reference: it bypasses TME suppression via ex vivo DC maturation and tumor lysate loading, ensuring controlled, Type 1-polarized instruction for robust, antigen-specific T-cell responses. This creates high-quality, persistent killers that infiltrate and remodel the TME. In contrast, GVAX relies on in situ recruitment of endogenous DCs via GM-CSF-secreting tumor cells, which can be inconsistent in PDAC's myeloid-dominant TME, often yielding immature TLS or limited durability without additional agonists. From a systems engineering perspective, PDAC immunity is a feedback control system with faulty sensors (impaired endogenous DCs). DCVax acts as an external controller, injecting precise setpoints (mature DCs) to stabilize output (durable T-cell memory), while GVAX attempts gain amplification on noisy endogenous loops, risking instability.
UF Health Cancer Institute member @GahyunGim, a GI oncologist, discusses takeaways from the landmark phase 3 RASolute 302 trial at #ASCO26. "I'm so excited to bring this new technology and new science to my patients," she said.
#PancreaticCancer #PanCan #Daraxonrasib @ASCO @TGeorgeMD
Major news from #ASCO26: A multi-selective RAS(ON) inhibitor nearly doubles survival time in people with metastatic pancreatic cancer. “This is absolutely practice-changing” says @ShrutiPatelMD in this Science in Seconds. #pancan
Read the abstract: https://t.co/MbVCqGvYfz
In loving memory of my mother who passed away. We are past the halfway mark & just $2,605 away from covering her final services.
https://t.co/Br2n0b7sP3
#GoFundMe #PancreaticCancer #FuneralExpenses #MutualAid #MemorialFund #Crowdfunding #PleaseShare #PanCan #GoFundMeCampaign
In loving memory of my mother who passed away from pancreatic cancer. We are past the halfway mark & just $2,605
https://t.co/Br2n0b7sP3
#GoFundMe #PancreaticCancer #FuneralExpenses #MutualAid #MemorialFund #Crowdfunding #PleaseShare #InLovingMemory #PanCan #GoFundMeCampaign
Thank you for taking steps to end #pancreaticcancer at #PanCAN PurpleStride. All together, we can change the story of this disease! 👟
Fundraising for PurpleStride 2026 is still open, which means there’s still time to donate to a Strider, team or event. Registered Striders have until Sunday, May 31, to raise or self-donate $100+ to earn their official PanCAN PurpleStride 2026 T-shirt. Raise $1,000+ by Tuesday, June 30, to become a PanCAN PurpleStride 2026 Grand Club member and earn the exclusive Grand Club lightweight hoodie!
Your PanCAN PurpleStride 2026 participation ensured that progress against pancreatic cancer continues and that no one will have to navigate a diagnosis on their own. Thank you for giving hope to those who need it most. 💜
#PanCAN awareness 💜
Losing my beautiful aunt to this is horrible. And my grandma, her sister.
New Top Advances of the Year commentary 💡 Authors from @UTMDAnderson critically review recent & emerging data that have helped to define the current state of neoadjuvant management in pancreatic cancer: https://t.co/5GWboyZiVR
@OncoAlert #pancan
#pancan #Hogeyshomerunners @DrakeHogestyn Love seeing them to come together for such a great cause and honoring a great man. Too many have loss lives to Pancreatic cancer. I lost a dear friend last year, cancer stinks. Thank you @DaysPeacock Cast.@sappstick
Last Seen Hashtags on Sotwe
รับงานอ่าวอุดม
Seen from Thailand
pbrbunkhouse
Seen from United States
ankaratraveſti
Seen from Turkey
pochill
Seen from United States
jaihomodi
Seen from United States
AheadOfTheCurve
Seen from United States
momson filter:videos
Seen from Sweden
ilimited
Seen from United States
TamannaBhatia
Seen from Germany
ชักว่าวหน้าโถ
Seen from Thailand
Trends for you
Most Popular Users
Elon Musk 
@elonmusk
241.7M followers
Barack Obama
@barackobama
119M followers
Cristiano Ronaldo
@cristiano
114.4M followers
Donald J. Trump
@realdonaldtrump
111.9M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.7M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.8M followers
KATY PERRY
@katyperry
90M followers
Taylor Swift
@taylorswift13
84M followers
Lady Gaga
@ladygaga
75.4M followers
Virat Kohli
@imvkohli
73.4M followers
Kim Kardashian
@kimkardashian
70.9M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
66.4M followers
Bill Gates
@billgates
65.2M followers
Selena Gomez
@selenagomez
63.1M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.7M followers